Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECEDE: Ibudilast in Degenerative Cervical Myelopathy
NCT04631471Phase 3Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Dec 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibudilast in degenerative cervical myelopathy (DCM), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Dec 2021; status: recruiting.
02
Drugs
ibudilast
03
Conditions
degenerative cervical myelopathy (DCM)
Beyond the preview
Go deeper on NCT04631471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631471.